Feasibility of sentinel lymph node biopsy for acquired clinical node-negative breast cancer after neoadjuvant therapy in node-positive breast cancer, multi-centric, single arm, phase II, confirmatory study

Feasibility of sentinel lymph node biopsy for acquired clinical node-negative breast cancer after neoadjuvant therapy in node-positive breast cancer, multi-centric, single arm, phase II, confirmatory study - Sentinel lymph node biopsy after neoadjuvant therapy in node-positive breast cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030510

Enrollment

Registered

2017-12-25

Start date

2018-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Sentinel lymph node biopsy

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Aquired clinical node negative breast cancer after neoadjuvant therapy

Exclusion criteria

Exclusion criteria: Inoperable case Inflammatory breast cancer Progressive disease after neoadjuvant therapy

Design outcomes

Primary

Measure	Time frame
3-year axillary lymph node relapse free survival	—

Secondary

Measure	Time frame
Diagnostic potential of SNB 3-year disease-free and overall survival Relation between relapse site and clinicopathological factor Rate of arm lymphedema	—

Countries

Japan

Contacts

Public ContactYoshinari Ogawa

Osaka City General Hospital Department of Breast Surgical Oncology

yos-ogawa@med.osakacity-hp.or.jp06-6929-1221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026